"Histologically, papillary carcinoma demonstrates "delicate stalks of epithelial cells" 3, which account for its name. Neoplastic papilla with central fibrovascular core lined by cells with follicular epithelial cell differentiation and unique nuclear features. Clear nuclear chromatin "Orphan Annie eye" and longitudinal nuclear grooves, nuclear overlapping, intranuclear pseudo-inclusions, as well as irregular nuclear contours are the specific findings of papillary thyroid carcinoma. Psammoma bodies are common in PTC and they are usually seen within the papillary structures or in the tumour stroma but not in the tumoural follicles. Psammoma bodies represent focal infarctions and calcified dead tips of papillae."
" Staging"
"When the tumour measures ≤10 mm, the terms papillary thyroid microcarcinoma (PTMC) 18 or micropapillary carcinoma (mPTC) 14 can be used 14."
"When the tumour measures ≤10 mm, the terms papillary thyroid microcarcinoma (PTMC) 18 or micropapillary carcinoma (mPTC) 14 can be used 14."
"When the tumour measures ≤10 mm, the terms papillary thyroid microcarcinoma (PTMC) 18 or micropapillary carcinoma (mPTC) 14 can be used 14."
"Papillary thyroid cancer (as is the case with follicular thyroid cancer) typically occurs in the middle-aged, with a peak incidence in the 3rd and 4th decades. It is more common in women, with an M: F ratio of 1:2.5 (range 1:1.6-3:1) 2."
"negative for: CK20 and calcitonin"
"Warthin-like variant"
"BRAFV600E is the most frequent mutated gene, occurring in 60% of cases. RAS mutation and rearrangement of the RET gene, particularly fusion with PTC1 and PTC2 genes, are common in papillary thyroid carcinoma. 17"
"BRAFV600E is the most frequent mutated gene, occurring in 60% of cases. RAS mutation and rearrangement of the RET gene, particularly fusion with PTC1 and PTC2 genes, are common in papillary thyroid carcinoma. 17"
"BRAFV600E is the most frequent mutated gene, occurring in 60% of cases. RAS mutation and rearrangement of the RET gene, particularly fusion with PTC1 and PTC2 genes, are common in papillary thyroid carcinoma. 17"
"Patients with papillary thyroid cancer have an elevated risk for a secondary primary cancer, e.g. breast, urinary tract, digestive system, haematolymphoid and skin cancers, and the risk persists for decades after the initial PTC diagnosis. Male gender and older age are recognised risks, except for breast cancer risk, which exclusively applies to females 15,22."
Expected headings
"Associations"
"Subtypes"
"Immunohistochemistry"
"Molecular pathology"
" Staging"
"Fine needle aspiration"
"FDG-PET"
"Complications"
"It accounts for most (~70%) of all thyroid neoplasms and 85% of all thyroid cancers 2,4. There are 45,000 cases in the United States every year, and this type of carcinoma has the fastest-increasing incidence of any malignancy in the thyroid ref."
"Papillary carcinoma has a tendency to metastasise early to local lymph nodes, with 50% (39-90% 2) of patients having nodal involvement at presentation 1 (cf. 10% for follicular thyroid cancer). These metastases are usually to the ipsilateral jugular chain (~88%) and are commonly confined to the mid and lower lymph node levels; namely levels III and IV (73%) 1."
"Lobectomy is used for unilateral, intrathyroidal, low-risk tumours"